Barclays’s Contineum Therapeutics CTNM Stock Holding History
Bought
Maintained
Sold
Other funds holding CTNM
Barclays's CTNM Position: Q3 2026 in Review
Barclays reduced its Contineum Therapeutics (CTNM) stake by 74% in Q3 2026, selling an estimated $641K and leaving 15,166 shares worth $204K. The position accounts for ﹤0.01% of the portfolio, ranked #3964.
Barclays first reported a position in CTNM in Q2 2024 and has held it in 10 quarters since. The position peaked at $953K in Q2 2026. 118 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.
- Barclays held 15,166 shares of Contineum Therapeutics worth $204K as of Q3 2026.
- Barclays sold 43,007 Contineum Therapeutics shares in Q3 2026, an estimated $641K.
- Contineum Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3964 holding.
- Barclays first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 10 quarters since.
- Barclays's Contineum Therapeutics position peaked at $953K in Q2 2026.
- 118 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.